Research ExplorerPublicationsThe clinical use of circulating tumor cells (CTCs) enumerati...

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Standard

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. / Cristofanilli, Massimo; Pierga, Jean-Yves; Reuben, James; Rademaker, Alfred; Davis, Andrew A; Peeters, Dieter J; Fehm, Tanja; Nolé, Franco; Gisbert-Criado, Rafael; Mavroudis, Dimitrios; Grisanti, Salvatore; Giuliano, Mario; Garcia-Saenz, Jose A; Stebbing, Justin; Caldas, Carlos; Gazzaniga, Paola; Manso, Luis; Zamarchi, Rita; de Lascoiti, Angela Fernandez; De Mattos-Arruda, Leticia; Ignatiadis, Michail; Cabel, Luc; van Laere, Steven J; Meier-Stiegen, Franziska; Sandri, Maria-Teresa; Vidal-Martinez, Jose; Politaki, Eleni; Consoli, Francesca; Generali, Daniele; Cappelletti, Maria Rosa; Diaz-Rubio, Eduardo; Krell, Jonathan; Dawson, Sarah-Jane; Raimondi, Cristina; Rutten, Annemie; Janni, Wolfgang; Munzone, Elisabetta; Carañana, Vicente; Agelaki, Sofia; Almici, Camillo; Dirix, Luc; Solomayer, Erich-Franz; Zorzino, Laura; Darrigues, Lauren; Reis-Filho, Jorge S; Gerratana, Lorenzo; Michiels, Stefan; Bidard, François-Clément; Pantel, Klaus.

In: CRIT REV ONCOL HEMAT, Vol. 134, 02.2019, p. 39-45.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Cristofanilli, M, Pierga, J-Y, Reuben, J, Rademaker, A, Davis, AA, Peeters, DJ, Fehm, T, Nolé, F, Gisbert-Criado, R, Mavroudis, D, Grisanti, S, Giuliano, M, Garcia-Saenz, JA, Stebbing, J, Caldas, C, Gazzaniga, P, Manso, L, Zamarchi, R, de Lascoiti, AF, De Mattos-Arruda, L, Ignatiadis, M, Cabel, L, van Laere, SJ, Meier-Stiegen, F, Sandri, M-T, Vidal-Martinez, J, Politaki, E, Consoli, F, Generali, D, Cappelletti, MR, Diaz-Rubio, E, Krell, J, Dawson, S-J, Raimondi, C, Rutten, A, Janni, W, Munzone, E, Carañana, V, Agelaki, S, Almici, C, Dirix, L, Solomayer, E-F, Zorzino, L, Darrigues, L, Reis-Filho, JS, Gerratana, L, Michiels, S, Bidard, F-C & Pantel, K 2019, 'The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper', CRIT REV ONCOL HEMAT, vol. 134, pp. 39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004

APA

Cristofanilli, M., Pierga, J-Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Giuliano, M., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., ... Pantel, K. (2019). The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. CRIT REV ONCOL HEMAT, 134, 39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004

Vancouver

Cristofanilli M, Pierga J-Y, Reuben J, Rademaker A, Davis AA, Peeters DJ et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. CRIT REV ONCOL HEMAT. 2019 Feb;134:39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004

Bibtex

@article{33488632d5a24e00bd9f3abe56e59c17,
title = "The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper",
abstract = "BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IVindolent vs. 18.7 months Stage IVaggressive, p < 0.0001). Moreover, patients with Stage IVindolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location.CONCLUSIONS: We confirm the identification of two subgroups of MBC, Stage IVindolent and Stage IVaggressive, independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.",
keywords = "Journal Article, Review",
author = "Massimo Cristofanilli and Jean-Yves Pierga and James Reuben and Alfred Rademaker and Davis, {Andrew A} and Peeters, {Dieter J} and Tanja Fehm and Franco Nol{\'e} and Rafael Gisbert-Criado and Dimitrios Mavroudis and Salvatore Grisanti and Mario Giuliano and Garcia-Saenz, {Jose A} and Justin Stebbing and Carlos Caldas and Paola Gazzaniga and Luis Manso and Rita Zamarchi and {de Lascoiti}, {Angela Fernandez} and {De Mattos-Arruda}, Leticia and Michail Ignatiadis and Luc Cabel and {van Laere}, {Steven J} and Franziska Meier-Stiegen and Maria-Teresa Sandri and Jose Vidal-Martinez and Eleni Politaki and Francesca Consoli and Daniele Generali and Cappelletti, {Maria Rosa} and Eduardo Diaz-Rubio and Jonathan Krell and Sarah-Jane Dawson and Cristina Raimondi and Annemie Rutten and Wolfgang Janni and Elisabetta Munzone and Vicente Cara{\~n}ana and Sofia Agelaki and Camillo Almici and Luc Dirix and Erich-Franz Solomayer and Laura Zorzino and Lauren Darrigues and Reis-Filho, {Jorge S} and Lorenzo Gerratana and Stefan Michiels and Fran{\c c}ois-Cl{\'e}ment Bidard and Klaus Pantel",
note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",
year = "2019",
month = feb,
doi = "10.1016/j.critrevonc.2018.12.004",
language = "English",
volume = "134",
pages = "39--45",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

AU - Cristofanilli, Massimo

AU - Pierga, Jean-Yves

AU - Reuben, James

AU - Rademaker, Alfred

AU - Davis, Andrew A

AU - Peeters, Dieter J

AU - Fehm, Tanja

AU - Nolé, Franco

AU - Gisbert-Criado, Rafael

AU - Mavroudis, Dimitrios

AU - Grisanti, Salvatore

AU - Giuliano, Mario

AU - Garcia-Saenz, Jose A

AU - Stebbing, Justin

AU - Caldas, Carlos

AU - Gazzaniga, Paola

AU - Manso, Luis

AU - Zamarchi, Rita

AU - de Lascoiti, Angela Fernandez

AU - De Mattos-Arruda, Leticia

AU - Ignatiadis, Michail

AU - Cabel, Luc

AU - van Laere, Steven J

AU - Meier-Stiegen, Franziska

AU - Sandri, Maria-Teresa

AU - Vidal-Martinez, Jose

AU - Politaki, Eleni

AU - Consoli, Francesca

AU - Generali, Daniele

AU - Cappelletti, Maria Rosa

AU - Diaz-Rubio, Eduardo

AU - Krell, Jonathan

AU - Dawson, Sarah-Jane

AU - Raimondi, Cristina

AU - Rutten, Annemie

AU - Janni, Wolfgang

AU - Munzone, Elisabetta

AU - Carañana, Vicente

AU - Agelaki, Sofia

AU - Almici, Camillo

AU - Dirix, Luc

AU - Solomayer, Erich-Franz

AU - Zorzino, Laura

AU - Darrigues, Lauren

AU - Reis-Filho, Jorge S

AU - Gerratana, Lorenzo

AU - Michiels, Stefan

AU - Bidard, François-Clément

AU - Pantel, Klaus

N1 - Copyright © 2018. Published by Elsevier B.V.

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IVindolent vs. 18.7 months Stage IVaggressive, p < 0.0001). Moreover, patients with Stage IVindolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location.CONCLUSIONS: We confirm the identification of two subgroups of MBC, Stage IVindolent and Stage IVaggressive, independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.

AB - BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IVindolent vs. 18.7 months Stage IVaggressive, p < 0.0001). Moreover, patients with Stage IVindolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location.CONCLUSIONS: We confirm the identification of two subgroups of MBC, Stage IVindolent and Stage IVaggressive, independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.

KW - Journal Article

KW - Review

U2 - 10.1016/j.critrevonc.2018.12.004

DO - 10.1016/j.critrevonc.2018.12.004

M3 - SCORING: Review article

C2 - 30771872

VL - 134

SP - 39

EP - 45

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

ER -